Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-11-28
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of bexarotene in preventing breast
cancer in patients at high risk for breast cancer. Bexarotene belongs to a class of drugs
that are called rexinoids, and it may reduce the incidence of breast tumors.